Ribociclib
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1004490/Cv/2'> | <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1004490/Cv/2'> | ||
| - | Ribociclib, sold under the brand name Kisqali, is a medication used for the treatment of certain kinds of breast cancer. Ribociclib inhibits the enzymes [[Cyclin Dependent Kinase-4|cyclin-dependent kinase 4]] (CDK4) and cyclin-dependent kinase 6 (CDK6). See also [https://en.wikipedia.org/wiki/Ribociclib Ribociclib] and [[CDK4]] | + | Ribociclib, sold under the brand name Kisqali, is a medication used for the treatment of certain kinds of breast cancer. Ribociclib inhibits the enzymes [[Cyclin Dependent Kinase-4|cyclin-dependent kinase 4]] (CDK4) and cyclin-dependent kinase 6 (CDK6).<ref name="a7">[https://www.hcp.novartis.com/products/kisqali/metastatic-breast-cancer/ "Kisqali (ribociclib) Treatment: HR+/HER2- mBC". Novartis. Retrieved 24 August 2021.]</ref> See also [https://en.wikipedia.org/wiki/Ribociclib Ribociclib] and [[CDK4]] |
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 11:50, 30 October 2023
| |||||||||||
